Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 16
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Reseñas

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Unique Continuation for Locally Uniformly Distributed Measures

  • Engelstein, Max|||0000-0003-3234-1144
  • Guillén Mola, Ignasi|||0000-0002-1681-7002
In this note we show that the support of a locally k-uniform measure in Rn+1 satisfies a kind of unique continuation property. As a consequence, we show that locally uniformly distributed measures satisfy a weaker unique continuation property. This continues work of Kirchheim and Preiss (Math Scand 90(1): 152-160, 2002) and David, Kenig and Toro (Comm Pure Appl Math 54(4): 385-449, 2001) and lends additional evidence to the conjecture proposed by Kowalski and Preiss (J Reine Angew Math 379: 115-151, 1987) that each connected component of the support of a locally n-uniform measure in Rn+1 is contained in the zero set of a quadratic polynomial.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The dimension of planar elliptic measures arising from Lipschitz matrices in Reifenberg flat domains

  • Guillen Mola, Ignasi|||0000-0002-1681-7002
  • Prats, Martí|||0000-0001-8799-6995
  • Tolsa Domènech, Xavier|||0000-0001-7976-5433
In this paper we show that, given a planar Reifenberg flat domain with small constant and a divergence form operator associated to a real (not necessarily symmetric) uniformly elliptic matrix with Lipschitz coefficients, the Hausdorff dimension of its elliptic measure is at most 1. More precisely, we prove that there exists a subset of the boundary with full elliptic measure and with σ-finite one-dimensional Hausdorff measure. For Reifenberg flat domains, this result extends a previous work of Thomas H. Wolff for the harmonic measure.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Log-moment estimators of the Nakagami-lognormal distribution

  • Reig, Juan|||0000-0003-4541-9326
  • Rodrigo Peñarrocha, Vicent Miquel|||0000-0002-8075-4851
  • Rubio Arjona, Lorenzo|||0000-0003-3882-4673
  • Brennan, Conor
[EN] In this paper, estimators of the Nakagami-lognormal (NL) distribution based on the method of log-moments have been derived and thoroughly analyzed. Unlike maximum likelihood (ML) estimators, the log-moment estimators of the NL distribution are obtained using straightforward equations with a unique solution. Also, their performance has been evaluated using the sample mean, confidence regions and normalized mean square error (NMSE). The NL distribution has been extensively used to model composite small-scale fading and shadowing in wireless communication channels. This distribution is of interest in scenarios where the small-scale fading and the shadowing processes cannot be easily separated such as the vehicular environment., This work has been funded in part by the Programa de Estancias de Movilidad de Profesores e Investigadores en Centros Extranjeros de Ensenanza Superior e Investigacion of the Ministerio de Educacion, Cultura y Deporte, Spain, PR2015-00151 and by the Ministerio de Economia, Industria y Competitividad of the Spanish Government under the national project TEC2017-86779-C2-2-R, through the Agencia Estatal de Investigacion (AEI) and the Fondo Europeo de Desarrollo Regional (FEDER).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

RGD-dendrimer-poly(L-lactic) acid nanopatterned substrates for the early chondrogenesis of human mesenchymal stromal cells derived from osteoarthritic and healthy donors

  • Rodríguez-Pereira, Cristina
  • Lagunas, Anna
  • Casanellas, Ignasi
  • Vida, Yolanda
  • Pérez-Inestrosa, Ezequiel
  • Andrades, José A.
  • Becerra, José
  • Samitier, Josep
  • Blanco García, Francisco J
  • Magalhães, Joana
[Abstract] Aiming to address a stable chondrogenesis derived from mesenchymal stromal cells (MSCs) to be applied in cartilage repair strategies at the onset of osteoarthritis (OA), we analyzed the effect of arginine–glycine–aspartate (RGD) density on cell condensation that occurs during the initial phase of chondrogenesis. For this, we seeded MSC-derived from OA and healthy (H) donors in RGD-dendrimer-poly(L-lactic) acid (PLLA) nanopatterned substrates (RGD concentrations of 4 × 10−9, 10−8, 2.5 × 10−8, and 10−2 w/w), during three days and compared to a cell pellet conventional three-dimensional culture system. Molecular gene expression (collagens type-I and II–COL1A1 and COL2A1, tenascin-TNC, sex determining region Y-box9-SOX9, and gap junction protein alpha 1–GJA1) was determined as well as the cell aggregates and pellet size, collagen type-II and connexin 43 proteins synthesis. This study showed that RGD-tailored first generation dendrimer (RGD-Cys-D1) PLLA nanopatterned substrates supported the formation of pre-chondrogenic condensates from OA- and H-derived human bone marrow-MSCs with enhanced chondrogenesis regarding the cell pellet conventional system (presence of collagen type-II and connexin 43, both at the gene and protein level). A RGD-density dependent trend was observed for aggregates size, in concordance with previous studies. Moreover, the nanopatterns’ had a higher effect on OA-derived MSC morphology, leading to the formation of bigger and more compact aggregates with improved expression of early chondrogenic markers., This research was funded by the CIBER-BBN Intramural Projects Program (CHONDRONANONET). CIBER-BBN is a national initiative of ISCIII. The authors further acknowledge funds from the INTERREG V cooperation program for Spain–Portugal (POCTEP) 2014–2020 project (0245_IBEROS_1_E), MINECO (CTQ2016-75870-P), Junta de Andalucía (UMA18-FEDERJA-007), CERCA Program, and by the Commission for Universities and Research of the Department of Innovation, Universities, and Enterprise of the Generalitat de Catalunya (2017 SGR 1079). This work was developed in the context of AdvanceCat with the support of ACCIÓ 17 (Catalonia Trade and Investment; Generalitat de Catalunya) under the Catalonian ERDF operational program 2014–2020. C.R.P. acknowledges support from the i-PFIS Doctoral Program (IFI15/00151) funded by ISCIII. I.C. acknowledges support from MINECO through the Subsidies for Predoctoral Contracts for the Training of Doctors open call, co-funded by the European Social Fund (2016), Junta de Andalucía; UMA18-FEDERJA-007, Generalitat de Catalunya; 2017 SGR 1079
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Numerical simulation of transcranial static magnetic fields for the treatment of global epilepsy in children

  • Paz, C.
  • Suárez Porto, Eduardo
  • Rivadulla, Casto
[Abstract] Transcranial static magnetic stimulation has shown the capacity to decrease systematically the cortical excitability in the treatment of epilepsy. Nevertheless, the application of these therapies to non-focal epilepsies is limited. This paper investigates on the numerical evaluation of promising strategies based on the application of static magnetic fields with multiple magnets on children. Results show that a ten-magnet configuration on the child's head generates a magnetic flux density of 0.10 T in more than 70% of the brain cortex and more than 0.05 T in deep areas near the brain's base. Conversely, the interaction between individual magnetic fields leads to regions of lower flux density, suggesting that not only the number of magnets, but also their relative position and orientation, are critical parameters. Thus, based on image diagnosis, it is possible to define a personalising procedure and develop an effective therapy of global epilepsy that penetrates sufficiently into the brain´s volume., This work was funded by the Instituto de Salud Carlos III, PI21/00151, co-funded by the European Union and XUGA ED431C 2022/05.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Transcranial static magnetic stimulation reduces seizures in a mouse model of Dravet syndrome

  • Rivadulla, Casto
  • Pardo-Vázquez, José Luís
  • Labra, Carmen de
  • Aguilar, J.
  • Suárez, Eduardo
  • Paz, Concepción
  • Álvarez-Dolado, Manuel
  • Cudeiro, Javier
Dravet syndrome is a rare form of severe genetic epilepsy characterized by recurrent and long-lasting seizures. It appears around the first year of life, with a quick evolution toward an increase in the frequency of the seizures, accompanied by a delay in motor and cognitive development, and does not respond well to antiepileptic medication. Most patients carry a mutation in the gene SCN1A encoding the α subunit of the voltage-gated sodium channel Nav1.1, resulting in hyperexcitability of neural circuits and seizure onset. In this work, we applied transcranial static magnetic stimulation (tSMS), a non-invasive, safe, easy-to-use and affordable neuromodulatory tool that reduces neural excitability in a mouse model of Dravet syndrome. We demonstrate that tSMS dramatically reduced the number of crises. Furthermore, crises recorded in the presence of the tSMS were shorter and less intense than in the sham condition. Since tSMS has demonstrated its efficacy at reducing cortical excitability in humans without showing unwanted side effects, in an attempt to anticipate a possible use of tSMS for Dravet Syndrome patients, we performed a numerical simulation in which the magnetic field generated by the magnet was modeled to estimate the magnetic field intensity reached in the cerebral cortex, which could help to design stimulation strategies in these patients. Our results provide a proof of concept for nonpharmacological treatment of Dravet syndrome, which opens the door to the design of new protocols for treatment., Instituto de salud Carlos III (ISCIII) PI21/00151, co-funded by the European Union Xunta de Galicia, Grupos de referencia competitiva 2021 ED431C 2022/05 (CR) Ministerio de Ciencia e Innovacion PID2019-108250RJ-100 Xunta de Galicia, Grupos con Pontencial Crecimiento 2021 (JPV). Apoyo Dravet (MAD). JPV has a contract under the Ramon y Cajal program (RYC2019–026380-I)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Study protocol for a randomised controlled trial: Treatment of early intrauterine growth restriction with low molecular weight heparin (TRACIP)

  • Mazarico, E.
  • Peguero, A.
  • Camprubí, M.
  • Rovira, C.
  • Gomez Roig, M.D.
  • Oros, D.
  • Ibáñez-Burillo, P.
  • Schoorlemmer, J.
  • Masoller, N.
  • Tàssies, M.D.
  • Figueras, F.
Introduction The incidence of intrauterine growth restriction (IUGR) is estimated at about 3% of pregnancies, and it is associated with 30% of all perinatal mortality and severe morbidity with adverse neurodevelopmental and cardiovascular health consequences in adult life. Early onset IUGR represents 20%-30% of all cases and is highly associated with severe placental insufficiency. The existing evidence suggests that low molecular weight heparin (LMWH) has effects beyond its antithrombotic action, improving placental microvessel structure and function of pregnant women with vascular obstetric complications by normalising proangiogenic and antiapoptotic protein levels, cytokines and inflammatory factors. The objective of our study is to demonstrate the effectiveness of LMWH in prolonging gestation in pregnancies with early-onset IUGR. Methods and analysis This is a multicentre, triple-blind, parallel-arm randomised clinical trial. Singleton pregnancies qualifying for early (20-32 weeks at diagnosis) placental IUGR (according to Delphi criteria) will be randomised to subcutaneous treatment with bemiparin 3500 IU/0.2 mL/day or placebo from inclusion at diagnosis to the time of delivery. Analyses will be based on originally assigned groups (intention-to-treat). The primary objective will be analysed by comparing gestational age and prolongation of pregnancy (days) in each group with Student''s t-tests for independent samples and by comparing Kaplan-Maier survival curves (from inclusion to delivery, log-rank test). A linear regression model for gestational age at birth will consider the following covariates: Gestational age at inclusion (continuous) and pre-eclampsia (binary). Ethics and dissemination The study will be conducted in accordance with the principles of Good Clinical Practice. This study was approved by the Clinical Research Ethics Committee (CEIC) of Sant Joan de Déu Hospital, on 13 July 2017. The trial is registered in the public registry www.clinicaltrial.gov. according to Science Law 14/2011, and the results will be published in an open access journal.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Shorter hepatitis B immunoglobulin administration is not associated to hepatitis B virus recurrence when receiving combined prophylaxis after liver transplantation

  • Lens, Sabela
  • García Eliz, María
  • Fernández Vázquez, María Inmaculada
  • Castells, Lluis
  • Bonacci, Martin
  • Mas, Antoni
  • Crespo, Gonzalo
  • Buti, María
  • Prieto, Martín
  • Forns, Xavier
Background & Aims: The combination of hepatitis B immunoglobulin and a nucleos(t)ide analogues has markedly reduced the rate of hepatitis B virus recurrence after liver transplantation; however, the optimal duration of hepatitis B immunoglobulin has not been clarified. This lack of consensus perpetuates the use of different strategies. The aim of this study was to evaluate the risk factors associated to hepatitis B virus recurrence after liver transplantation in a large cohort of patients under different hepatitis B immunoglobulin regimens. Methods: Retrospective multicentre analysis of hepatitis B virus-related liver transplantation recipients receiving combined prophylaxis (hepatitis B immunoglobulin + nucleos(t)ide analogues). The strategy of short-term hepatitis B immunoglobulin was compared to lifelong administration. Hepatitis B virus recurrence was defined as positive HBsAg after liver transplantation. Results: Three hundred and thirty-eight patients were analysed. After a median follow-up period of 72 months, 37 patients (11%) developed hepatitis B virus recurrence. Hepatocellular carcinoma recurrence and lamivudine resistance after liver transplantation were the only factors independently associated to hepatitis B virus recurrence (HR 5.4 [2.3-12] and 9.3 [4.2-20] respectively P < .001). HBsAg reappearance after hepatitis B virus recurrence was transient (16 patients), persistent (15) or alternant (6). The hepatitis B immunoglobulin regimen did not have an impact on the rate or evolution of hepatitis B virus recurrence. Overall, patient survival was good and not influenced by hepatitis B virus recurrence (82% at 5 years). Fulminant liver failure, hepatitis C coinfection or hepatocellular carcinoma at liver transplantation were independent risk factors for lower survival. Conclusions: Liver transplantation is an effective treatment for hepatitis B virus-related liver disease. Since the introduction of combined prophylaxis the rate of hepatitis B virus recurrence is very low. However, lifelong hepatitis B immunoglobulin administration does not seem necessary to reduce hepatitis B virus recurrence.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Hereditary Optic Neuropathies: A Systematic Review on the Interplay between Biomaterials and Induced Pluripotent Stem Cells

  • Ladero Galán, Miguel
  • Reche Sainz, José Alberto
  • Galardo Pérez, María Esther
Hereditary optic neuropathies (HONs) such as dominant optic atrophy (DOA) and Leber Hereditary Optic Neuropathy (LHON) are mitochondrial diseases characterized by a degenerative loss of retinal ganglion cells (RGCs) and are a cause of blindness worldwide. To date, there are only limited disease-modifying treatments for these disorders. The discovery of induced pluripotent stem cell (iPSC) technology has opened several promising opportunities in the field of HON research and the search for therapeutic approaches. This systematic review is focused on the two most frequent HONs (LHON and DOA) and on the recent studies related to the application of human iPSC technology in combination with biomaterials technology for their potential use in the development of RGC replacement therapies with the final aim of the improvement or even the restoration of the vision of HON patients. To this purpose, the combination of natural and synthetic biomaterials modified with peptides, neurotrophic factors, and other low- to medium-molecular weight compounds, mimicking the ocular extracellular matrices, with human iPSC or iPSC-derived cell retinal progenitors holds enormous potential to be exploited in the near future for the generation of transplantable RGC populations.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

La influència del català sobre el lèxic castellà, visió diacrònica

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Hepatitis C virus intrinsic molecular determinants may contribute to the development of cholestatic hepatitis after liver transplantation

  • Gambato, Martina
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Quer, Josep|||0000-0003-0014-084X
  • Koutsoudakis, George
  • González, Patricia
  • Caro-Pérez, Noelia
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • García-González, Neris
  • González-Candelas, Fernando|||0000-0002-0879-5798
  • Ignacio Esteban, Juan
  • Crespo, Gonzalo|||0000-0002-1178-4897
  • Navasa, Miquel|||0000-0002-3130-9604
  • Forns, Xavier|||0000-0002-8188-1764
  • Pérez-Del-Pulgar, Sofía
Cholestatic hepatitis C (CHC) is a severe form of hepatitis C virus (HCV) infection recurrence that leads to high graft loss rates early after liver transplantation (LT). To investigate the pathogenic mechanisms of CHC, we analysed HCV quasispecies in CHC patients compared to a control group (mild hepatitis C recurrence) by deep pyrosequencing. At the time of LT, NS5B quasispecies complexity was similar between the two groups but, after LT, it decreased more sharply in CHC patients than in the control group. Interestingly, the major variant before LT propagated efficiently and remained as the dominant sequence after LT in 62% of CHC patients versus 11% of controls (P=0.031). Sequence analysis of the complete nonstructural region in a limited number of patients revealed a potential 12 aa signature specific to the CHC group. These data suggest that intrinsic molecular determinants in the circulating HCV quasispecies may provide a fitness advantage, contributing to the development of CHC.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals

  • Egmond, Elfi|||0000-0003-1897-0067
  • Mariño, Zoe|||0000-0001-6321-9534
  • Navinés, Ricard|||0000-0002-6999-7510
  • Oriolo, Giovanni
  • Pla, Anna
  • Bartres, Concepció
  • Lens, Sabela|||0000-0003-4900-411X
  • Forns, Xavier|||0000-0002-8188-1764
  • Martin-Santos, Rocio|||0000-0003-4150-4726
Depression has been associated with hepatitis C, as well as with its treatment with proinflammatory cytokines (i.e., interferon). The new direct-acting antiviral agents (DAAs) have minimal adverse effects and high potency, with a direct inhibitory effect on non-structural viral proteins. We studied the incidence and associated factors of depression in a real-life prospective cohort of chronic hepatitis C patients treated with the new DAAs. The sample was recruited from a cohort of 91 patients with hepatitis C, of both sexes, with advanced level of fibrosis and no HIV coinfection, consecutively enrolled during a 6-month period for DAA treatment; those euthymic at baseline (n=54) were selected. All were evaluated through the depression module of the Patient Health Questionnaire (PHQ-9-DSM-IV), at three time points: baseline, 4 weeks, and end-of-treatment. The cumulative incidence (95%CI) of major depression and any depressive disorder during DAA treatment was 13% (6.4-24.4) and 46.3% (33.7-59.4), respectively. No differences were observed between those patients with and without cirrhosis or ribavirin treatment (p.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients

  • García López, Mireia|||0000-0002-9643-7172
  • Lens, Sabela|||0000-0003-4900-411X
  • Pallett, Laura J.
  • Testoni, Barbara
  • Rodríguez-Tajes, Sergio|||0000-0002-3189-7557
  • Mariño, Zoe|||0000-0001-6321-9534
  • Bartres, Concepció
  • García-Pras, Ester
  • Leonel, Thais
  • Perpiñán, Elena
  • Lozano, Juan José
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Koutsoudakis, George
  • Zoulim, Fabien
  • Maini, Mala K.
  • Forns, Xavier|||0000-0002-8188-1764
  • Pérez-Del-Pulgar, Sofía
Factors associated with a successful outcome upon nucleos(t)ide analogue (NA) treatment withdrawal in HBeAg-negative chronic hepatitis B (CHB) patients have yet to be clarified. The objective of this study was to analyse the HBV-specific T cell response, in parallel with peripheral and intrahepatic viral parameters, in patients undergoing NA discontinuation. Twenty-seven patients without cirrhosis with HBeAg-negative CHB with complete viral suppression (.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Erratum, Neutrophil and monocyte function in patients with chronic hepatitis C undergoing antiviral therapy with regimens containing protease inhibitors with and without interferon (PLoS ONE (2016) 11:11 (e0166631) DOI: 10.1371/journal.pone.0166631)

  • Gambato, Martina
  • Caro-Pérez, Noelia
  • González, Patricia
  • Cañete Hidalgo, Nuria|||0000-0001-9501-7590
  • Mariño, Zoe|||0000-0001-6321-9534
  • Lens, Sabela|||0000-0003-4900-411X
  • Bonacci, Martín
  • Bartres, Concepció
  • Sánchez Tapias, José María
  • Carrión Rodríguez, José Antonio|||0000-0001-7191-6081
  • Forns, Xavier|||0000-0002-8188-1764
  • Juan, Manel|||0000-0002-3064-1648
  • Pérez-Del-Pulgar, Sofía
  • Londoño, Maria Carlota|||0000-0002-6533-1586
There are errors in the Funding section. The correct funding information is as follows: SPP has received a grant from Instituto de Salud Carlos III, Ministerio de Economía y Competitividad (PI13/00155), co-funded by Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea, Una manera de hacer Europa. XF has received a grant from L' Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) (2014-SGR-605). XF was also supported in part by grant PI15/00151, integrated in Plan Nacional de I+D+I and funded by ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER-"Una manera de Hacer Europa"). MG was funded with an EASL Entry Level Research Fellowship (Dame Sheila Sherlock EASL Fellowship Programme).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Beneficial Effects of Glucagon-Like Peptide-1 (GLP-1) in Diabetes-Induced Retinal Abnormalities, Involvement of Oxidative Stress

  • Ramos, Hugo|||0000-0001-6443-7576
  • Bogdanov, Patricia|||0000-0003-0669-4958
  • Sampedro, Joel|||0000-0002-8463-7740
  • Huerta, Jordi|||0000-0002-9908-8051
  • Simó Canonge, Rafael|||0000-0003-0475-3096
  • Hernández, Cristina|||0000-0002-3109-1721
Background: Hyperglycemia-induced oxidative stress plays a key role in diabetic complications, including diabetic retinopathy. The main goal of this study was to assess whether the topical administration (eye drops) of glucagon-like peptide-1 (GLP-1) has any effect on oxidative stress in the retina. Methods: db/db mice were treated with eye drops of GLP-1 or vehicle for three weeks, with db/+ mice being used as control. Studies included the assessment by western blot of the antioxidant defense markers CuZnSOD, MnSOD, glutathione peroxidase and reductase; immunofluorescence measurements of DNA/RNA damage, nitro tyrosine and Ki67 and Babam2 proteins. Results: GLP-1 eye drops protected from oxidative stress by increasing the protein levels of glutathione reductase, glutathione peroxidase and CuZnSOD and MnSOD in diabetic retinas. This was associated with a significant reduction of DNA/RNA damage and the activation of proteins involved in DNA repair in the retina (Babam2) and Ki67 (a biomarker of cell proliferation). Conclusions: GLP-1 modulates the antioxidant defense system in the diabetic retina and has a neuroprotective action favoring DNA repair and neuron cells proliferation.